Lilly's Remternetug TRAILRUNNER-ALZ 1 Readout Expected H1 2026. Eli Lilly's next-generation anti-amyloid antibody targeting pyroglutamate amyloid-beta is being trialed in 1,600+ patients with early symptomatic Alzheimer's. This Phase III study assesses both SC and IV formulations, with subcutaneous delivery potentially offering ARIA risk advantages. If positive, remternetug could launch as Lilly's successor to Kisunla with a differentiated safety and convenience profile.

AbbVie Tavapadon NDA Under FDA Review. The first-in-class D1/D5 receptor partial agonist for Parkinson's disease has its NDA under FDA review, with a PDUFA decision expected H1 2026. TEMPO program data showed -10.3 point improvement in MDS-UPDRS Parts II+III scores (vs -1.2 placebo) as monotherapy, and +1.1 hours additional ON time without troublesome dyskinesia as adjunctive therapy. Long-term TEMPO-4 OLE data confirmed a favorable sustained safety profile.

Sanofi Tolebrutinib FDA Resolution Expected Q1 2026. Following the December CRL, Sanofi continues discussions with the FDA and has submitted an expanded access protocol for nrSPMS patients. The agency's decision on a path forward — whether additional data, a new trial, or an advisory committee meeting — will set the tone for the entire BTK inhibitor class in MS. The EU regulatory review remains ongoing.

Claseprubart Heads to Phase 3 in Myasthenia Gravis. Dianthus Therapeutics reported positive Phase 2 MaGic trial results, with claseprubart (a selective C1s complement inhibitor) achieving 4.6-point improvement in MG-ADL scores (placebo-adjusted 1.8 points; P=.0013) at just 13 weeks. The company plans an end-of-Phase 2 meeting with FDA and expects Phase 3 CAPTIVATE CIDP data in H2 2026.

Lundbeck Pivots Bocunebart to IV, Resetting Phase 2b Timeline. After subcutaneous dosing of the anti-PACAP antibody failed to demonstrate the desired treatment effect in interim analysis, Lundbeck is now focusing on intravenous delivery, which showed prior Phase 2 success. Phase 2b completion now expected H1 2026; Phase 3 initiation H2 2026 if data support advancement.

Lecanemab Mechanism of Action Defined in Nature Neuroscience. VIB/KU Leuven researchers published the first mechanistic explanation of how anti-amyloid antibodies clear plaques, demonstrating that lecanemab's Fc fragment activates human microglia to clear amyloid. An Fc-fragment-deficient version had no effect, confirming immune activation is central to efficacy. This finding has implications for next-generation antibody engineering to potentially reduce ARIA while maintaining plaque clearance.

Alzheimer's Treatment-to-Target Race Heats Up. With Leqembi SC autoinjector approved and weekly dosing sBLA pending, Eisai/Biogen push for greater treatment convenience. Lilly's remternetug (TRAILRUNNER-ALZ 1 readout imminent) and Roche's trontinemab (brain shuttle technology for enhanced BBB penetration) represent the next competitive wave. The emerging anti-tau combination strategy — BMS-986446/etalanetug received FDA Fast Track for use alongside Leqembi — signals a shift toward polytherapy models that could expand the addressable Alzheimer's market. Drug repurposing also draws attention: an expert Delphi panel identified sildenafil, Zostavax, and riluzole as the top three candidates for Alzheimer's repositioning.

Myasthenia Gravis Market Crowding Intensifies. The gMG competitive landscape saw major moves: Amgen secured EC approval for Uplizna (inebilizumab) in AChR+ and MuSK+ gMG with twice-yearly maintenance dosing; Regeneron's cemdisiran (quarterly SC siRNA) plans a US regulatory submission in Q1 2026 after positive NIMBLE Phase 3 data; and argenx's Vyvgart franchise continues expanding with the CIDP approval. argenx maintains first-mover advantage across gMG and CIDP, but quarterly dosing from Regeneron and twice-yearly dosing from Amgen create meaningful competitive pressure on treatment burden and compliance.

CGRP Market Matures; Safety Monitoring Becomes Key Differentiator. Eight FDA-approved CGRP therapeutics now compete across acute and preventive segments, with the American Headache Society recommending CGRP drugs as first-line preventive therapy. The emerging cardiovascular safety signal (aHR 1.3 for composite CV events) may create differentiation opportunities between monoclonal antibodies and small-molecule gepants, and between CGRP-targeting and PACAP-targeting approaches. Gepants (rimegepant, atogepant, zavegepant) gain relative advantage from dual acute/preventive utility and absence of the rebound headache risk seen with older therapies.

BTK Inhibitor Class Navigates Liver Safety Hurdle. Liver toxicity remains the defining regulatory challenge for the entire BTK class in MS. Tolebrutinib's HERCULES trial reported ALT >3× ULN in 4.0% of patients (vs 1.6% placebo), including one fatal liver failure case. Fenebrutinib faced an FDA partial clinical hold in 2023 for similar concerns. Companies with cleaner hepatic profiles will gain significant regulatory and commercial advantages. Roche's fenebrutinib appears best positioned for first-to-market BTK status, while Novartis's remibrutinib (already approved in CSU) brings a known safety database advantage.

H1 2026 Regulatory Calendar: Three Major PDUFA Dates. AbbVie's tavapadon (PD), Eisai's Leqembi weekly SC dosing (AD), and the tolebrutinib resolution path (MS) all converge in the first half of 2026. Lilly's TRAILRUNNER-ALZ 1 Phase III readout for remternetug could also land in this window, potentially establishing a third competitive anti-amyloid antibody. The Annovis Bio buntanetap Phase III 6-month symptomatic readout is expected H2 2026.

Anti-Tau Combination Strategy Emerges as Next AD Frontier. BMS-986446/etalanetug's Fast Track designation for use alongside Leqembi signals the industry's pivot toward anti-amyloid + anti-tau polytherapy. If the Tau NexGen Phase 2/3 trial validates this approach in dominantly inherited AD, it could reshape the commercial Alzheimer's market from single-agent competition to combination regimen positioning. Biogen's BIIB080 tau-targeting ASO (CELIA trial) adds another combination-ready asset.

PACAP Inhibitors Set to Define Next-Generation Migraine Treatment. With Slate Medicines ($130M Series A) and Lundbeck (bocunebart IV pivot) both advancing PACAP-targeting programs, 2026 will clarify whether PACAP blockade can serve the 20-30% of CGRP non-responders. Combination CGRP + PACAP inhibitor studies remain theoretically attractive but await safety data. If the CGRP cardiovascular signal is confirmed in larger studies, PACAP may gain additional differentiation.

Complement Inhibitor Competition Intensifies Across gMG, NMOSD, CIDP. Ravulizumab (AstraZeneca) posted Phase 3 CHAMPION-NMOSD data with zero relapses in 58 patients over 73 weeks. Cross-indication platform expansion — argenx in gMG+CIDP, Regeneron targeting gMG+PNH — creates commercial moats. The emergence of CAR-T approaches in autoimmune neurology (IASO Bio's CT103A in NMOSD) represents a longer-term but potentially disruptive modality shift.

Parkinson's Disease-Modification Gap Remains the Industry's Largest Unmet Need. Despite 63 disease-modifying programs in clinical development, only 3 are in Phase 3. Biogen/Denali's BIIB122 (LRRK2 inhibitor, LUMA trial) expected to complete by March 2026. GLP-1 receptor agonists (exenatide, lixisenatide) continue to generate excitement for PD neuroprotection, leveraging the massive diabetes/obesity trial infrastructure. A positive GLP-1 signal in PD could redirect billions in investment toward repurposing strategies.